The National Eczema Association has released a report documenting state-by-state disparities in access to care for Americans living with atopic dermatitis, the chronic inflammatory skin disease that affects a substantial share of the U.S. population and ranks among the most common reasons for dermatology visits.

The report, highlighted by Dermatology Times, frames access to atopic dermatitis care as geographically uneven. Where a patient lives, the analysis indicates, shapes how readily they can reach clinicians equipped to manage the disease — from general dermatologic care to advanced therapies such as biologic agents and systemic treatments used for moderate-to-severe disease.

For dermatology practices, the state-level framing carries practical weight. Access gaps of this kind typically translate into diagnostic delay, under-treatment of moderate-to-severe disease, and heavier reliance on emergency departments or primary care for flares that specialty clinicians could manage more effectively. Atopic dermatitis care has grown markedly more complex over the past decade, with an expanding armamentarium of targeted agents; distribution of that armamentarium is only as good as the workforce and referral pathways available in a given state.

What does the report highlight?

The National Eczema Association, the leading patient-advocacy organization for eczema in the United States, compiled the report to make geographic disparities visible at the state level rather than in national averages. National statistics, patient organizations have long argued, can mask concentrated shortfalls in specific regions — rural areas in particular — where dermatologist density, insurance coverage patterns, and referral networks all constrain access.

The report's core message: atopic dermatitis care is not equally reachable across states, and patients in some regions face materially greater barriers than others.

Why state-level access data matter for clinicians

For practicing dermatologists, the findings arrive amid a broader conversation about workforce distribution and access in the specialty. Several dynamics shape whether a patient with atopic dermatitis actually reaches appropriate care:

• Geographic distribution of board-certified dermatologists, which skews toward metropolitan areas
• Insurance design, including prior-authorization requirements that delay initiation of systemic and biologic therapy
• Referral pathways from primary care, which influence how quickly moderate-to-severe disease reaches specialty management
• Patient education and awareness, which affect whether symptoms are recognized as treatable rather than endured

Each of these factors varies by state, which is precisely the variation the NEA report puts on the record.

The clinical stakes of delayed access

Atopic dermatitis is a chronic, relapsing inflammatory disease, and the consequences of delayed specialty care are well documented in the dermatology literature: uncontrolled pruritus and sleep disruption, increased skin infections, measurable effects on quality of life, and progression of disease severity that becomes harder to reverse. Access gaps therefore function as a clinical variable, not merely an administrative one.

Patient-organization reporting of the kind the NEA has produced serves a second purpose for clinicians: it supplies state-level evidence that practices, health systems, and policymakers can cite when arguing for expanded telehealth coverage, better reimbursement pathways, or residency and workforce programs targeted to underserved states.

What comes next

The report positions the National Eczema Association to press for policy responses keyed to the specific states where gaps are widest, and dermatology practices in those states may find it a useful instrument in conversations with payers and legislators about access. As the data circulate through clinical and advocacy channels, watch for state-level initiatives — and payer responses — aimed at closing the documented gaps in atopic dermatitis care.